CAPRICOR THERAPEUTICS INC. - COMMON STOCK

The Lancet Publishes Positive Results from Capricor Therapeutics’ Phase 2 Study Evaluating CAP-1002 in Late-Stage Duchenne Muscular Dystrophy

11 Mar 2022 07:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

10 Mar 2022 15:01:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on March 10

03 Mar 2022 08:15:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Names Dr. Daniel Paulson as Vice President of Clinical Development

02 Mar 2022 08:00:01 By Nasdaq GlobeNewswire

Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in the U.S.

25 Jan 2022 04:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Key Updates on its Vaccine and Therapeutic Programs for COVID-19

13 Dec 2021 08:15:00 By Nasdaq GlobeNewswire

Capricor’s CEO Dr. Linda Marbán to Serve as Keynote Speaker at TriLink Annual mRNA Day

12 Nov 2021 08:15:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

09 Nov 2021 15:05:02 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present Third Quarter 2021 Financial Results and Recent Corporate Update on November 9

02 Nov 2021 15:05:01 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002

24 Sep 2021 06:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present at the Upcoming Investor and Industry Healthcare Conferences

22 Sep 2021 15:05:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

07 Sep 2021 08:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present Final Data from HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society 2021

02 Sep 2021 07:30:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

12 Aug 2021 15:01:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12

05 Aug 2021 08:00:00 By Nasdaq GlobeNewswire

Capricor Announces Joint Publication with the US Army Institute of Surgical Research for Cardiosphere-Derived Exosomes as a Potential Therapeutic for Shock

04 Aug 2021 07:00:01 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces the Appointment of Karimah Es Sabar to its Board of Directors

27 Jul 2021 07:00:04 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present Findings from HOPE-2 Open-Label Extension Study at Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference

17 Jun 2021 08:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Participate in BIO Digital 2021 Conference

10 Jun 2021 08:15:00 By Nasdaq GlobeNewswire

Capricor To Present Preclinical Data for Exosome-mRNA Vaccine for SARS-CoV-2 at the International Society for Extracellular Vesicles (ISEV) Annual Meeting

18 May 2021 07:30:00 By Nasdaq GlobeNewswire